Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

In vitro susceptibility of Trypanosoma cruzi discrete typing units (DTUs) to benznidazole: A systematic review and meta-analysis
Andrea Vela, Marco Coral-Almeida, Denis Séréno, et al.
PLoS neglected tropical diseases (2021) Vol. 15, Iss. 3, pp. e0009269-e0009269
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

Efficacy of three benznidazole dosing strategies for adults living with chronic Chagas disease (MULTIBENZ): an international, randomised, double-blind, phase 2b trial
Pau Bosch‐Nicolau, Marisa Fernández, Elena Sulleiro, et al.
The Lancet Infectious Diseases (2024) Vol. 24, Iss. 4, pp. 386-394
Closed Access | Times Cited: 23
Diretriz da SBC sobre Diagnóstico e Tratamento de Pacientes com Cardiomiopatia da Doença de Chagas – 2023
José Antônio Marin‐Neto, Anis Rassi, Gláucia Maria Moraes de Oliveira, et al.
Arquivos Brasileiros de Cardiologia (2023) Vol. 120, Iss. 6
Open Access | Times Cited: 39
Chagas disease in the United States: a call for increased investment and collaborative research
Nelson Iván Agudelo Higuita, Norman Beatty, Colin Forsyth, et al.
The Lancet Regional Health - Americas (2024) Vol. 34, pp. 100768-100768
Open Access | Times Cited: 9
Expression Analysis of Thirteen Genes in Response to Nifurtimox and Benznidazole in Mexican Isolates of Trypanosoma cruzi by Digital PCR
Paulina Ochoa‐Martínez, Aracely López‐Monteon, Jaime López‐Domínguez, et al.
Acta Parasitologica (2025) Vol. 70, Iss. 1
Closed Access | Times Cited: 1
Fifteen Years after the Definition of Trypanosoma cruzi DTUs: What Have We Learned?
Bianca Zingales, Andréa Mara Macedo
Life (2023) Vol. 13, Iss. 12, pp. 2339-2339
Open Access | Times Cited: 21
State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation
Juan Carlos Gabaldón-Figueira, Nieves Martínez-Peinado, Elisa Escabia, et al.
Research and Reports in Tropical Medicine (2023) Vol. Volume 14, pp. 1-19
Open Access | Times Cited: 19
Enhancing Trypanosomatid Identification and Genotyping with Oxford Nanopore Sequencing
Lissa Cruz‐Saavedra, Carlos Ospina, Luz Helena Patiño, et al.
Journal of Molecular Diagnostics (2024) Vol. 26, Iss. 5, pp. 323-336
Open Access | Times Cited: 7
Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status
Fernanda Karoline Vieira da Silva Torchelsen, Ana Lia Mazzeti, Vanessa Carla Furtado Mosqueira
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 575-590
Closed Access | Times Cited: 7
New drug discovery strategies for the treatment of benznidazole-resistance in Trypanosoma cruzi , the causative agent of Chagas disease
Silvane Maria Fonseca Murta, Pedro Augusto Lemos Santana, Thibault Joseph William Jacques Dit Lapierre, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 6, pp. 741-753
Closed Access | Times Cited: 6
Cardiac involvement in Chagas disease and African trypanosomiasis
Éster Cerdeira Sabino, Maria Carmo Pereira Nunes, Johannes Blum, et al.
Nature Reviews Cardiology (2024) Vol. 21, Iss. 12, pp. 865-879
Closed Access | Times Cited: 6
Unveiling Drimenol: A Phytochemical with Multifaceted Bioactivities
Zhongming Yang, Kim Wei Chan, Md Zuki Abu Bakar, et al.
Plants (2024) Vol. 13, Iss. 17, pp. 2492-2492
Open Access | Times Cited: 6
Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations
Davi Alvarenga Lima, Leilane Oliveira Gonçalves, João Luís Reis-Cunha, et al.
Parasites & Vectors (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 16
System-based insights into parasitological and clinical treatment failure in Chagas disease
Linda M. Ernst, Giovana C. Macedo, Laura‐Isobel McCall
mSystems (2025)
Closed Access
Coinfection by multiple Trypanosoma cruzi clones: a new perspective on host-parasite relationship with consequences for pathogenesis and management of Chagas disease
Yves Carlier, Eric Dumonteil, Claudia Herrera, et al.
Microbiology and Molecular Biology Reviews (2025)
Closed Access
Highly abundant bacteria in the gut of Triatoma dimidiata (Hemiptera: Reduviidae) can inhibit the growth of Trypanosoma cruzi (Kinetoplastea: Trypanosomatidae)
Juan Carlos Cambronero-Heinrichs, Diego Rojas‐Gätjens, Mónica Baizán, et al.
Journal of Medical Entomology (2024) Vol. 61, Iss. 6, pp. 1333-1344
Open Access | Times Cited: 3
In Vitro Antiprotozoal Activity of Schinus molle Extract, Partitions, and Fractions against Trypanosoma cruzi
Nancy E. Rodríguez-Garza, Ramiro Quintanilla‐Licea, Ricardo Gómez-Flores, et al.
Plants (2024) Vol. 13, Iss. 16, pp. 2177-2177
Open Access | Times Cited: 3
Exploring Contact Toxicity of Essential Oils against Sitophilus zeamais through a Meta-Analysis Approach
Fernanda Achimón, María Laura Peschiutta, Vanessa Daniela Brito, et al.
Plants (2022) Vol. 11, Iss. 22, pp. 3070-3070
Open Access | Times Cited: 15
Fumigant toxicity of essential oils against Sitophilus zeamais (Motschulsky) (Coleoptera: Curculionidae): a systematic review and meta-analysis
María Laura Peschiutta, Fernanda Achimón, Vanessa Daniela Brito, et al.
Journal of Pest Science (2021) Vol. 95, Iss. 3, pp. 1037-1056
Closed Access | Times Cited: 20
Potential of sulfur-selenium isosteric replacement as a strategy for the development of new anti-chagasic drugs
Mercedes Rubio-Hernández, Verónica Alcolea, Silvia Pérez‐Silanes
Acta Tropica (2022) Vol. 233, pp. 106547-106547
Open Access | Times Cited: 11
Direct evidence gap on fixed versus adjusted‐dose benznidazole for adults with chronic Chagas disease without cardiomyopathy: Systematic review and individual patient data meta‐analysis
Agustín Ciapponi, Fabiana Barreira, Lucas Perelli, et al.
Tropical Medicine & International Health (2022) Vol. 28, Iss. 1, pp. 2-16
Closed Access | Times Cited: 9
Strasseriolides display in vitro and in vivo activity against trypanosomal parasites and cause morphological and size defects in Trypanosoma cruzi
Cristina Bosch‐Navarrete, Guiomar Pérez‐Moreno, Frederick Annang, et al.
PLoS neglected tropical diseases (2023) Vol. 17, Iss. 9, pp. e0011592-e0011592
Open Access | Times Cited: 5
Fifteen Years after the Definition of <em>Trypanosoma cruzi </em>DTUs: What Have We Learned?
Bianca Zingales, Andréa Mara Macedo
(2023)
Open Access | Times Cited: 5
Clinical use of molecular methods for Trypanosoma cruzi infection in endemic and non-endemic countries: Benefits, limitations and challenges
María‐Jesús Pinazo, Colin Forsyth, Constanza Lopez-Albízu, et al.
Frontiers in Parasitology (2023) Vol. 2
Open Access | Times Cited: 4
Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease
Gláucia Diniz Alessio, Carolina Malheiros Araújo Silvestrini, Silvana Maria Elói-Santos, et al.
PLoS neglected tropical diseases (2024) Vol. 18, Iss. 9, pp. e0012487-e0012487
Open Access | Times Cited: 1
What are the translational challenges associated with Chagas disease drug discovery?
Inmaculada Ramírez-Macías, Paola García‐Huertas, Clotilde Marı́n
Expert Opinion on Drug Discovery (2024), pp. 1-4
Closed Access | Times Cited: 1
Page 1 - Next Page

Scroll to top